Disadvantages of LDN
As an off-label and treatment medicine for pain, low-dose naltrexone does offer some disadvantages. The disadvantages that might limit the use of LDN will be discussed in this blog.
Patients are preparing their dosages.
When prescribing, LDN is not available commercially in a 4.5mg dose, which would be ideal for managing chronic pain. So, several individuals might try to produce their quantity by dividing 50mg tablets. Internet sources that describe the method of breaking 50mg tablets or forming a solution and dividing the liquid doses have been discovered. Such approaches are possible to lead patients to unintended day-to-day variability in the dosing. The damage of such inconsistency is lessened by the fact that the dangers of an overdose of low-dose naltrexone are very unlikely to happen. However, patients taking charge of creating doses themselves is far from optimal.
Lack of adequate dosage-finding experiments
It is hugely presumable that 4.5mg is not an optimal dosage for every individual for chronic pain management, as it is unique for this medicine to have a one-size-fits-all dose. Additionally, to standard variables like body mass index, patients might differ in their metabolism, microglia sensitivity, or opioid receptor sensitivity to LDN. Individuals who give no response to 4.5 mg daily might likely respond to either more low or higher doses. Other dosing plans, like twice a day, have yet not been investigated in clinical studies. Proper dosing research needs to be conducted to ascertain the therapeutic index of the medicine and to identify a method for preparing an individual’s dosage.
No solid data on long-term safe use
Even if naltrexone owns a history of safe use with a broad range of high dosages, we have very little knowledge about the long-term safety profile of the medicine when used for a long time in low dosages. The low dosage is usually quoted as a reason for clinicians and subjects to not be worried about safety. But, we must be open to the chance that the rare clinical outcomes possible with even low dosage can also offer new health risks. There are no noted serious concerns till now. While repression of immune system parameters could apparently raise the chance of getting infections or cancer because of reduced immunosurveillance, no reports of such adverse effects at any dose of naltrexone have been reported.
It is not facilitated by insurance companies.
As a non-FDA, off-label treatment, LDN might not be covered by insurance companies. As the low average cost of LDN therapy might make it easily available, but still, there can undoubtedly be a considerable number of people who might find even US$35/month to be prohibitively costly. Hence, the potential absence of insurance coverage is a drawback of LDN.
Reference post link: http://harborcompounding1.simplesite.com/449281115